Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes

Journal of the National Cancer Institute

Volumn 93, Issue 2, 2001, Pages 112-120

  Fisher, Bernard ^a   Dignam, James ^b   Tan Chiu, Elizabeth ^c   Anderson, Stewart ^b   Fisher, Edwin R ^c   Wittliff, James L ^d   Wolmark, Norman ^c  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXTRAN; ESTRADIOL; ESTROGEN RECEPTOR; FLUOROURACIL; FOLINIC ACID; LIGAND; METHOTREXATE; PROGESTERONE RECEPTOR; SUCROSE; TAMOXIFEN;

ADULT; AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE MANAGEMENT; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; INFORMATION PROCESSING; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR CLASSIFICATION; TUMOR VOLUME;

EID: 0035900920     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.2.112     Document Type: Article

References (42)

1. Cancer of the breast: Size of neoplasm and prognosis
2. Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy
3. 1-phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings
4. Combination chemotherapy as an adjuvant treatment in operable breast cancer
5. Adjuvant chemotherapy for breast cancer
6. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer
7. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study
8. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors
9. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil
10. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
11. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
12. Predictors of recurrence in stage I (T1N0M0) breast carcinoma
13. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma
14. Factors influencing survival and prognosis in early breast carcinoma (T1N0M0-T1N1M0). Assessment of 644 patients with median follow-up of 18 years
15. Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone
16. Primary tumor size. Relevance to breast cancer survival
17. Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up
18. Treatment and survival of female patients with nonpalpable breast carcinoma
19. Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0)
20. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bN0M0): Clinicopathologic features and outcome
21. Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter
22. Predicting recurrence in axillary-node negative breast cancer patients
23. Node-negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy
24. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
25. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer
26. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer
27. Methods of steroid receptor analyses and their quality control in the clinical laboratory
28. Establishment of uniformity in steroid receptor determinations for protocol B-09 of the national surgical adjuvant breast project
29. Steroid hormone receptors
30. Influence of biopsy size on sex-steroid receptor levels determined by enzyme immunoassay
31. Nonparametric estimation from incomplete observations
32. On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data
33. Regression models and life-tables
34. Late mortality from T1N0M0 breast carcinoma
35. Development and use of a natural history data base of breast cancer studies
36. Meeting highlights: International consensus panel on the treatment of primary breast cancer
37. Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10 mm or less detected clinically and by screening
38. Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up
39. Prognostic factors for patients with breast cancers 1 cm and smaller
40. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma
41. Histopathology grading in small breast cancers ≤ 10 mm-results from an area with mammography screening
42. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas